Posted on Tuesday, July 03, 2018 By Nicola Westgate
'A Diamond does not start out polished and shining, but with enough pressure, hard work and time it becomes brilliant'
Kite Pharma secures breakthrough European positive opinion for CAR-T cell cancer therapy.
Posted on Monday, April 30, 2018 By Nicola Westgate
Congratulations to Public Health England (PHE) for winning the British Expertise International Awards 2018 under “international healthcare project” category for “Fast-track global collaborations to conquer emergencies such as Ebola and Zika”. PHE’s Senior Business Development Manager Professor S.S. Vasan collected the award on his team’s behalf from HRH The Duke of Gloucester KG GCVO on 12 April 2018.
Thanking his colleagues “who have made such a difference to our response to Ebola and Zika crises”, Professor Vasan said, “The aspect of our project we are most proud of is collaborations. It is absolutely essential when you are facing a global emergency like Ebola or Zika that we set aside differences, and we keep the focus on saving lives and working in collaboration with industry, academia and non-profit sector so that the response can be very effective and very quick. Every minute saves lives, literally, in this case.” & ...
Posted on Thursday, March 29, 2018 By Nicola Westgate
Barbara Fallowfield, Commercial Manager of Mologic was recently interviewed by Anna Macdonald of Technology Networks where they discussed issues clinicians face whilst under pressure to prescribe antibiotics, and how a recent partnership between Fraunhofer UK, and Mologic can help tackle those issues.
Posted on Tuesday, January 30, 2018 By Nicola Westgate
Oxford, UK, 24 January 2018 - Oxfordshire companies which have progressed valuable innovations over the
past three years can apply now for The Oxford Science Park Innovation Award, one of 2018's Oxfordshire
Business Awards. Open to companies of any size and from any sector, the deadline for applications is March 2.
This is the third year that The Oxford Science Park, one of the UK's leading parks for science and technology
companies, has sponsored the Innovation Award.
What The Oxford Science Park's judges will be looking for is the development and/or launch within the past
three years of an innovative product, process, service or business method. The development should have a
quantifiable benefit, both actual and projected, against key performance indicators for the applicant
organisation1. Last year's winner was Perspectum Diagnostics, which detects and measures liver and biliary
diseases using medical physics and image analysis. Other entries have come from industries as diverse ...
Posted on Wednesday, July 19, 2017 By Nicola Westgate
For the full news article, please see http://www.bbc.co.uk/news/in-pictures-40582699
Posted on Friday, July 07, 2017 By Nicola Westgate
Leadership in place; Clinical Operations teams growing throughout Europe
BETHESDA, Md., July 6, 2017 /PRNewswire/ -- Precision for Medicine today reported important progress in its global expansion plan. Precision for Medicine, with its oncology research team Precision Oncology, is rapidly expanding its global footprint to better serve clients developing oncology treatments. Investment in executive leadership and operational teams are underway across Europe, providing integrated, full-service clinical trial execution services throughout the continent.
Posted on Wednesday, July 05, 2017 By Nicola Westgate
Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce it has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). During this collaboration, Exscientia will apply its AI enabled platform and combine this with the expertise of GSK, in order to discover novel and selective small molecules for up to 10 disease-related targets, nominated by GSK across multiple therapeutic areas.
Posted on Thursday, May 25, 2017 By Nicola Westgate
Beamline Diagnostics, developers of an innovative biopsy triaging system, founded by Dr. Liberty Foreman and Dr. Katherine Willetts, has closed a £650k investment round which was led by a syndicate of Angels in MedCity (AiMC) and other investors.
Posted on Tuesday, May 16, 2017 By Nicola Westgate
Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that it has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.
Delivery of new therapies for metabolic disease (such as diabetes) is hampered by a paucity of single targets that are amenable to drug discovery. To address this challenge, Exscientia will apply its unique platform to identify and validate combinations of drug targets* that could work synergistically and be amenable to Exscientia’s powerful bispecific-small-molecule design strategy – where a small molecule is designed to be compatible with two distinct drug targets.
Starting with over a thousand disease-relevant target combinations, Exscientia will triage opportunities and prioritise those with promising bispecific binding potential. Target pairs fulfilling these initial tractability criteria will pa ...
Posted on Thursday, May 11, 2017 By Nicola Westgate
Oxford, UK: CREDOS announces the launch of ‘Biotherapeutics News and Views’. Published quarterly, this newsletter will aim to cover key topics in the biopharmaceutical industry. CREDOS is a specialist consultancy tailored to the discovery and development of biological therapeutics (www.credos-bio.co.uk)